Hemogenyx Historical Income Statement

HEMO Stock

343.40 20.90 6.48%

Historical analysis of Hemogenyx Pharmaceuticals income statement accounts such as Other Operating Expenses of 6.8 M or Total Operating Expenses of 6.8 M can show how well Hemogenyx Pharmaceuticals PLC performed in making a profits. Evaluating Hemogenyx Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Hemogenyx Pharmaceuticals's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Hemogenyx Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Hemogenyx Pharmaceuticals is a good buy for the upcoming year.

Net Income Gross Profit

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hemogenyx Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Hemogenyx Income Statement Analysis

Hemogenyx Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Hemogenyx Pharmaceuticals shareholders. The income statement also shows Hemogenyx investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Hemogenyx Pharmaceuticals Income Statement Chart

At this time, Hemogenyx Pharmaceuticals' Cost Of Revenue is comparatively stable compared to the past year. Minority Interest is likely to gain to 6,106 in 2024, despite the fact that EBIT is likely to grow to (6.1 M).

Interest Expense Total Operating Expenses Income Before Tax Selling And Marketing Expenses Research Development Net Income Applicable To Common Shares

Interest Expense

The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Income Before Tax

Income Before Tax which can also be referred as pre-tax income is reported on Hemogenyx Pharmaceuticals income statement and is an important metric when analyzing Hemogenyx Pharmaceuticals profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.

Net Income Applicable To Common Shares

The net income that remains after preferred dividends have been deducted, available to common shareholders.

Most accounts from Hemogenyx Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Hemogenyx Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hemogenyx Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Hemogenyx Pharmaceuticals income statement Correlations

	Selling General Administrative	Other Operating Expenses	Operating Income	Ebit	Ebitda	Total Operating Expenses	Income Before Tax	Net Income	Depreciation And Amortization	Selling And Marketing Expenses	Gross Profit	Total Other Income Expense Net	Income Tax Expense	Interest Income	Net Income From Continuing Ops	Research Development	Minority Interest	Net Interest Income	Reconciled Depreciation
Selling General Administrative		0.88	-0.8	-0.93	-0.93	0.97	-0.89	-0.8	0.83	0.84	-0.3	-0.12	0.06	0.97	-0.9	0.88	0.55	-0.18	0.99
Other Operating Expenses	0.88		-0.52	-0.99	-0.99	0.96	-0.94	-0.87	0.87	0.92	-0.7	-0.1	0.16	0.77	-0.94	0.72	0.61	-0.2	0.9
Operating Income	-0.8	-0.52		0.63	0.64	-0.72	0.64	0.58	-0.37	-0.46	-0.24	0.2	-0.07	-0.8	0.64	-0.78	-0.18	0.26	-0.75
Ebit	-0.93	-0.99	0.63		1.0	-0.99	0.95	0.88	-0.84	-0.9	0.6	0.12	-0.14	-0.83	0.95	-0.79	-0.58	0.2	-0.93
Ebitda	-0.93	-0.99	0.64	1.0		-0.99	0.96	0.89	-0.83	-0.9	0.58	0.14	-0.15	-0.82	0.95	-0.79	-0.57	0.22	-0.93
Total Operating Expenses	0.97	0.96	-0.72	-0.99	-0.99		-0.95	-0.87	0.84	0.89	-0.48	-0.13	0.13	0.89	-0.95	0.83	0.57	-0.22	0.97
Income Before Tax	-0.89	-0.94	0.64	0.95	0.96	-0.95		0.98	-0.73	-0.93	0.52	0.42	-0.38	-0.77	1.0	-0.7	-0.66	0.45	-0.86
Net Income	-0.8	-0.87	0.58	0.88	0.89	-0.87	0.98		-0.63	-0.93	0.49	0.56	-0.57	-0.67	0.97	-0.58	-0.7	0.62	-0.76
Depreciation And Amortization	0.83	0.87	-0.37	-0.84	-0.83	0.84	-0.73	-0.63		0.84	-0.63	0.14	-0.07	0.82	-0.76	0.66	0.62	0.03	0.88
Selling And Marketing Expenses	0.84	0.92	-0.46	-0.9	-0.9	0.89	-0.93	-0.93	0.84		-0.62	-0.34	0.45	0.75	-0.95	0.6	0.82	-0.48	0.83
Gross Profit	-0.3	-0.7	-0.24	0.6	0.58	-0.48	0.52	0.49	-0.63	-0.62		-0.08	-0.1	-0.17	0.51	-0.15	-0.49	-0.02	-0.37
Total Other Income Expense Net	-0.12	-0.1	0.2	0.12	0.14	-0.13	0.42	0.56	0.14	-0.34	-0.08		-0.79	-0.03	0.41	0.04	-0.42	0.82	-0.01
Income Tax Expense	0.06	0.16	-0.07	-0.14	-0.15	0.13	-0.38	-0.57	-0.07	0.45	-0.1	-0.79		-0.05	-0.38	-0.18	0.51	-0.97	-0.02
Interest Income	0.97	0.77	-0.8	-0.83	-0.82	0.89	-0.77	-0.67	0.82	0.75	-0.17	-0.03	-0.05		-0.79	0.86	0.53	-0.09	0.97
Net Income From Continuing Ops	-0.9	-0.94	0.64	0.95	0.95	-0.95	1.0	0.97	-0.76	-0.95	0.51	0.41	-0.38	-0.79		-0.7	-0.68	0.45	-0.88
Research Development	0.88	0.72	-0.78	-0.79	-0.79	0.83	-0.7	-0.58	0.66	0.6	-0.15	0.04	-0.18	0.86	-0.7		0.39	0.04	0.86
Minority Interest	0.55	0.61	-0.18	-0.58	-0.57	0.57	-0.66	-0.7	0.62	0.82	-0.49	-0.42	0.51	0.53	-0.68	0.39		-0.51	0.53
Net Interest Income	-0.18	-0.2	0.26	0.2	0.22	-0.22	0.45	0.62	0.03	-0.48	-0.02	0.82	-0.97	-0.09	0.45	0.04	-0.51		-0.09
Reconciled Depreciation	0.99	0.9	-0.75	-0.93	-0.93	0.97	-0.86	-0.76	0.88	0.83	-0.37	-0.01	-0.02	0.97	-0.88	0.86	0.53	-0.09

Click cells to compare fundamentals

Hemogenyx Pharmaceuticals Account Relationship Matchups

Hemogenyx Pharmaceuticals income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Interest Expense	31.3K	33.2K	2.6M	33.0	316.0K	365.3K
Selling General Administrative	429.1K	623.8K	1.4M	942.4K	4.9M	5.2M
Other Operating Expenses	1.7M	2.2M	2.8M	5.5M	6.5M	6.8M
Operating Income	(1.7M)	(2.2M)	(2.7M)	4.0M	(6.5M)	(6.1M)
Ebit	(1.5M)	(2.1M)	(2.5M)	(4.0M)	(6.4M)	(6.1M)
Ebitda	(1.4M)	(2.0M)	(2.4M)	(3.4M)	(5.7M)	(5.4M)
Total Operating Expenses	1.2M	1.9M	2.5M	2.9M	6.5M	6.8M
Income Before Tax	(1.5M)	(2.1M)	(5.1M)	(4.0M)	(6.7M)	(6.4M)
Net Income	(1.5M)	(2.1M)	(7.5M)	(4.3M)	(6.7M)	(6.4M)
Depreciation And Amortization	94.7K	106.8K	126.3K	564.1K	645.7K	678.0K
Selling And Marketing Expenses	14.6K	33.5K	4.2K	4.9M	5.6M	5.9M
Gross Profit	(421.8K)	(350.7K)	(283.6K)	(2.6M)	(645.7K)	(678.0K)
Total Other Income Expense Net	196.0K	55.4K	(2.4M)	10.6K	(230.6K)	(242.2K)
Income Tax Expense	(35K)	20.4K	2.4M	361.2K	(5.8K)	(5.5K)
Interest Income	14.2K	3.4K	18.0K	10.6K	85.3K	89.6K
Net Income From Continuing Ops	(1.5M)	(2.1M)	(5.1M)	(4.0M)	(6.7M)	(6.4M)
Research Development	21.25	83.66	37.58	402.94	90.6K	95.2K
Cost Of Revenue	421.8K	350.7K	283.6K	2.6M	645.7K	653.2K
Net Income Applicable To Common Shares	(1.5M)	(1.5M)	(2.1M)	(5.1M)	(4.6M)	(4.4M)
Net Interest Income	(17.1K)	(29.9K)	(2.6M)	10.6K	(230.6K)	(242.2K)
Reconciled Depreciation	94.7K	106.8K	126.3K	195.2K	645.7K	678.0K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Hemogenyx Stock Analysis

When running Hemogenyx Pharmaceuticals' price analysis, check to measure Hemogenyx Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hemogenyx Pharmaceuticals is operating at the current time. Most of Hemogenyx Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hemogenyx Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hemogenyx Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hemogenyx Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC